ÂÜÀòÂÒÂ×

Arthur Stril currently serves as the Chief Financial Officer (interim) and Chief Business Officer at Cellectis since July 2018, alongside a role as a Board Member at Primera Therapeutics. Prior to these positions, Arthur Stril held significant roles including VP of Corporate Development at Cellectis and Ingénieur des Mines with the Corps des Mines, a prestigious technical branch of the French State, from September 2010 to June 2018. Additional experience includes serving as Head of Unit for Hospital Financing at the Ministère des solidarités et de la santé and as a Case Handler for Pharma Merger Control at the European Commission. Educational qualifications include a Chief Financial Officer Program in Accounting and Finance at Columbia University (2024-2025), DU in Immunotherapy and Immuno-oncology from Université Paris-Saclay (2019-2021), a Master's in Mathematics from the University of Cambridge (2009-2010), and a Master's in Physics from Ecole normale supérieure (2007-2010).